A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Sara M TolaneySolmaz SahebjamEmilie Le RhunThomas BachelotPeter KabosAhmad AwadaDenise YardleyArlene ChanPierfranco ConteVéronique DiérasNancy U LinMelissa BearSonya C ChapmanZhengyu YangYanyun ChenCarey K Anders

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

This study did not meet its primary endpoint. Abemaciclib was associated with an iCBR of 24% in patients with heavily pretreated HR+, HER2- MBC. Abemaciclib achieved therapeutic concentrations in brain metastases tissue, far exceeding those necessary for CDK4 and CDK6 inhibition. Further studies are warranted, including assessing novel abemaciclib-based combinations.

Keyphrases

brain metastases
small cell lung cancer
phase ii study
positive breast cancer
cell cycle
open label
randomized controlled trial
cell proliferation
clinical trial
radiation therapy
case control
placebo controlled
study protocol